CHG预激方案联合甲磺酸伊马替尼治疗慢性粒细胞白血病急髓变疗效观察  

Effect of CHG priming regimen plus imatinib mesylate on myeloid blastic phase of chronic myeloid leukemia

作　　者：张诚[1] 

机构地区：[1]南阳医学高等专科学校第一附属医院血液科,河南南阳473000

出　　处：《中华实用诊断与治疗杂志》2014年第4期409-410,共2页Journal of Chinese Practical Diagnosis and Therapy

摘　　要：目的探讨CHG（阿糖胞苷＋羟基喜树碱＋重组人粒细胞刺激因子）预激方案联合甲磺酸伊马替尼治疗慢性粒细胞白血病急髓变的效果。方法慢性粒细胞白血病急髓变患者26例，均给予CHG预激方案联合甲磺酸伊马替尼方案治疗，连续用药14d，间隔28d，4个周期后评定治疗效果，并随访观察生存情况。结果26例均完成4个周期治疗，其中回转至慢性期者18例，回转至加速期者4例，无效者4例，总有效率为84．6％；随访36个月，26例患者2a存活9例，中位生存时间20（8～31）个月，完全缓解者中位血液学复发时间9（2～21）个月。结论CHG方案联合甲磺酸伊马替尼是治疗慢性粒细胞白血病急髓变的有效方法。Objective To explore the effect of CHG regimen （cytarabine ＋ hydroxycamptothecin＋ recombinant human granulocyte colony stimulating factor） plus imatinib mesylate on myeloid blastic phase of chronic myeloid leukemia （CML）. Methods Twenty-six patients in myeloid blastic phase of CML received CHG regimen chemotherapy plus imatinib mesylate for 14 days, with an interval of 28 days. The therapeutic effect was assessed after 4 cycles. And the survival was observed. Results All patients completed 4 cycles of chemotherapy, in which 18 patients turned to chronic phase, 4 turned to accelerated phase, and 4 had no remission. The total effective rate was 84.6%. After the follow up survey for 36 months, 9 out of 26 patients survived for 2 years. The median survival time was 20 （8 to 31） months, and the median hematologic relapse time in complete hematologic remission patients was 9 （2 to 21） months. Conclusions CHG regimen plus imatinib mesylate is effective for myeloid blastic phase of CML.

关 键 词：慢性粒细胞白血病 急髓变 伊马替尼 CHG方案 

分 类 号：R733.7[医药卫生—肿瘤]